Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Celularity, Inc. (CELU : NSDQ)
 
 • Company Description   
Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.

Number of Employees: 115

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.87 Daily Weekly Monthly
20 Day Moving Average: 199,868 shares
Shares Outstanding: 28.95 (millions)
Market Capitalization: $25.19 (millions)
Beta: 0.44
52 Week High: $4.35
52 Week Low: $0.71
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.31% -26.11%
12 Week -29.83% -35.13%
Year To Date -21.61% -25.57%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
170 PARK AVE
-
FLORHAM PARK,NJ 07932
USA		 ph: 908-768-2170
fax: -		 carlos.ramirez@celularity.com http://www.celularity.com
 
 • General Corporate Information   
Officers
Robert J. Hariri - Chief Executive Officer and Chairman of the Board
John M. Sprague - Chief Financial Officer
Vincent LeVien - Director
Diane Parks - Director
Geoffrey Ling - Director

Peer Information
Celularity, Inc. (CORR.)
Celularity, Inc. (RSPI)
Celularity, Inc. (CGXP)
Celularity, Inc. (BGEN)
Celularity, Inc. (GTBP)
Celularity, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 151190204
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 09/04/26
Share - Related Items
Shares Outstanding: 28.95
Most Recent Split Date: 2.00 (0.10:1)
Beta: 0.44
Market Capitalization: $25.19 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 0.95
EPS Growth
vs. Year Ago Period: -20.55%
vs. Previous Quarter: 13.73%
Sales Growth
vs. Year Ago Period: -77.37%
vs. Previous Quarter: -22.33%
ROE
03/31/26 - -
12/31/25 - -
09/30/25 - -
ROA
03/31/26 - -
12/31/25 - -77.94
09/30/25 - -65.03
Current Ratio
03/31/26 - -
12/31/25 - 0.15
09/30/25 - 0.16
Quick Ratio
03/31/26 - -
12/31/25 - 0.15
09/30/25 - 0.12
Operating Margin
03/31/26 - -
12/31/25 - -345.45
09/30/25 - -198.75
Net Margin
03/31/26 - -
12/31/25 - -345.45
09/30/25 - -198.75
Pre-Tax Margin
03/31/26 - -
12/31/25 - -345.43
09/30/25 - -198.75
Book Value
03/31/26 - -
12/31/25 - -1.32
09/30/25 - -0.71
Inventory Turnover
03/31/26 - -
12/31/25 - 5.84
09/30/25 - 4.32
Debt-to-Equity
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Capital
03/31/26 - -
12/31/25 - -
09/30/25 - -
 

Powered by Zacks Investment Research ©